Loading company…
Sanegene Bio develops RNAi therapeutics using chemical modification and delivery platforms.
Sanegene Bio develops RNAi therapeutics and pharmaceuticals using chemical modification and hepatic and extrahepatic delivery platforms. Its clinical-stage candidate SGB-3403 is for hypercholesterolemia. Founded in 2021, the company is based in Woburn, US. In December 2025, it raised USD 110 million in Series B funding from Sino Biopharmaceutical Limited, Legend Capital, Vivo Capital, Invus Financial Advisors, SymBiosis Capital Management, Suzhou Capital Group, Trumed Investment Management, Hainan Zhenmai Private Equity Fund Management, Lake Bleu Capital, Eli Lilly & Company, GL Ventures and K2 Venture Partners, Hillhouse Investment, Qiming Venture Partners, TF Capital, Oriza FoFs, and NLVC.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in